|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||||||||
JOURNALS | ||||||||||||
  HepatologyCopyright © 2010 American Association for the Study of Liver Diseases Published on behalf of Journal Home | OnlineOpen | Society | News | Supporting Information Product Information | Editorial Board | For Authors | Access Policy | Subscribe | Advertise | Contact | Online Submission Current IssueVolume 51 Issue 2 (February 2010)Introduction to New SectionDiagnostic and therapeutic advances in hepatology: A new feature in the journal (p 363) Abstract | Full Text:
HTML,
PDF (Size: 37K)
 EditorialsGrowing old gracefully: Caring for the 90-year-old liver in the 40-year-old transplant recipient (p 364-365) Abstract | Full Text:
HTML,
PDF (Size: 45K)
Thiazolidinedione therapy for nonalcoholic steatohepatitis: Go, stop, or proceed with caution? (p 366-369) Abstract
|
References | Full Text:
HTML,
PDF (Size: 76K)
Transient elastography in nonalcoholic fatty liver disease: Making sense of echos (p 370-372) Abstract
|
References | Full Text:
HTML,
PDF (Size: 56K)
Long-term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance? (p 373-375) Abstract
|
References | Full Text:
HTML,
PDF (Size: 68K)
Making the liver what it is: The many targets of the transcriptional regulator HNF4 Abstract
|
References | Full Text:
HTML,
PDF (Size: 51K)
Viral HepatitisSelection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection (p 378-387) Abstract
|
References | Full Text:
HTML,
PDF (Size: 927K)
Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis (p 388-397) Abstract
|
References | Full Text:
HTML,
PDF (Size: 500K)
The heme oxygenase 1 product biliverdin interferes with hepatitis C virus replication by increasing antiviral interferon response (p 398-404) Abstract
|
References | Full Text:
HTML,
PDF (Size: 468K)
Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China (p 405-414) Abstract
|
References | Full Text:
HTML,
PDF (Size: 309K)
| Supporting information Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B (p 415-421) Abstract
|
References | Full Text:
HTML,
PDF (Size: 283K)
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B (p 422-430) Abstract
|
References | Full Text:
HTML,
PDF (Size: 372K)
Prevalence of hepatitis B surface antigen among refugees entering the United States between 2006 and 2008 (p 431-434) Abstract
|
References | Full Text:
HTML,
PDF (Size: 88K)
Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B (p 435-444) Abstract
|
References | Full Text:
HTML,
PDF (Size: 278K)
Steatohepatitis/Metabolic Liver DiseaseLong-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial (p 445-453) Abstract
|
References | Full Text:
HTML,
PDF (Size: 366K)
| Supporting information Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease (p 454-462) Abstract
|
References | Full Text:
HTML,
PDF (Size: 264K)
Lack of interleukin-6/glycoprotein 130/signal transducers and activators of transcription-3 signaling in hepatocytes predisposes to liver steatosis and injury in mice (p 463-473) Abstract
|
References | Full Text:
HTML,
PDF (Size: 2966K)
| Supporting information Toxicant-associated steatohepatitis in vinyl chloride workers (p 474-481) Abstract
|
References | Full Text:
HTML,
PDF (Size: 399K)
Gamma-glutamyltransferase and disability pension: A cohort study of construction workers in Germany (p 482-490) Abstract
|
References | Full Text:
HTML,
PDF (Size: 213K)
Variability in ethanol biodisposition in whites is modulated by polymorphisms in the ADH1B and ADH1C genes (p 491-500) Abstract
|
References | Full Text:
HTML,
PDF (Size: 307K)
| Supporting information Hemochromatosis in Italy in the last 30 years: Role of genetic and acquired factors (p 501-510) Abstract
|
References | Full Text:
HTML,
PDF (Size: 440K)
Kupffer cells promote hepatic steatosis via interleukin-1 Abstract
|
References | Full Text:
HTML,
PDF (Size: 2592K)
| Supporting information Hepatobiliary MalignanciesDown-regulation of connective tissue growth factor by inhibition of transforming growth factor Abstract
|
References | Full Text:
HTML,
PDF (Size: 5142K)
| Supporting information Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF- Abstract
|
References | Full Text:
HTML,
PDF (Size: 1878K)
| Supporting information Expression and functional significance of Twist1 in hepatocellular carcinoma: Its role in vasculogenic mimicry (p 545-556) Abstract
|
References | Full Text:
HTML,
PDF (Size: 6002K)
| Supporting information Loss of hepatocyte nuclear factor 1 Abstract
|
References | Full Text:
HTML,
PDF (Size: 1392K)
| Supporting information Autoimmune, Cholestatic and Biliary DiseaseCX3CL1 (fractalkine): A signpost for biliary inflammation in primary biliary cirrhosis (p 567-575) Abstract
|
References | Full Text:
HTML,
PDF (Size: 1193K)
Liver Failure/Cirrhosis/Portal HypertensionSystematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome (p 576-584) Abstract
|
References | Full Text:
HTML,
PDF (Size: 358K)
Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial (p 585-594) Abstract
|
References | Full Text:
HTML,
PDF (Size: 473K)
Decreased survival of subjects with elevated liver function tests during a 28-year follow-up (p 595-602) Abstract
|
References | Full Text:
HTML,
PDF (Size: 292K)
Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo (p 603-614) Abstract
|
References | Full Text:
HTML,
PDF (Size: 3753K)
| Supporting information Liver Injury/RegenerationOral medications with significant hepatic metabolism at higher risk for hepatic adverse events (p 615-620) Abstract
|
References | Full Text:
HTML,
PDF (Size: 109K)
| Supporting information Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury (p 621-632) Abstract
|
References | Full Text:
HTML,
PDF (Size: 4439K)
Liver Biology/PathobiologyThe homeobox gene Hex regulates hepatocyte differentiation from embryonic stem cell-derived endoderm (p 633-641) Abstract
|
References | Full Text:
HTML,
PDF (Size: 829K)
| Supporting information Integrated approach for the identification of human hepatocyte nuclear factor 4 Abstract
|
References | Full Text:
HTML,
PDF (Size: 2241K)
| Supporting information Rapid CommunicationHuh-7: A human Abstract
|
References | Full Text:
HTML,
PDF (Size: 687K)
AASLD Practice GuidelineDiagnosis and management of primary sclerosing cholangitis (p 660-678) Abstract
|
References | Full Text:
HTML,
PDF (Size: 282K)
ReviewsObesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications (p 679-689) Abstract
|
References | Full Text:
HTML,
PDF (Size: 640K)
Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: An analytical review (p 690-698) Abstract
|
References | Full Text:
HTML,
PDF (Size: 591K)
| Supporting information Diagnostic and Therapeutic Advances in HepatologyTolvaptan and hyponatremia in a patient with cirrhosis (p 699-702) Abstract
|
References | Full Text:
HTML,
PDF (Size: 706K)
Hepatology ElsewhereSnipping away at hepatitis C (p 703-705) Abstract
|
References | Full Text:
HTML,
PDF (Size: 656K)
Biting the iron bullet: Endoplasmic reticulum stress adds the pain of hepcidin to chronic liver disease (p 705-707) Abstract
|
References | Full Text:
HTML,
PDF (Size: 591K)
A glimpse of future hepatitis C virus treatment paradigms (p 707-710) Abstract
|
References | Full Text:
HTML,
PDF (Size: 75K)
Image of the MonthThe bright liver of glycogenic hepatopathy (p 711-712) Abstract
|
References | Full Text:
HTML,
PDF (Size: 581K)
CorrespondenceExtrahepatic conditions associated with primary biliary cirrhosis (p 713) Abstract
|
References | Full Text:
HTML,
PDF (Size: 45K)
The preferable treatment for cirrhotic portal vein thrombosis: Anticoagulation or transjugular intrahepatic portosystemic shunt? (p 713-714) Abstract
|
References | Full Text:
HTML,
PDF (Size: 147K)
Toll-like receptor 4: A starting point for proinflammatory signals in fatty liver disease (p 714-715) Abstract
|
References | Full Text:
HTML,
PDF (Size: 147K)
Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation (p 715-717) Abstract
|
References | Full Text:
HTML,
PDF (Size: 79K)
Serum markers of hepatocyte apoptosis: Current terminology and predictability in clinical practice (p 717-718) Abstract
|
References | Full Text:
HTML,
PDF (Size: 56K)
Comment on Abstract
|
References | Full Text:
HTML,
PDF (Size: 42K)
Carvedilol versus variceal band ligation for prevention of the first variceal bleed (p 718-719) Abstract
|
References | Full Text:
HTML,
PDF (Size: 52K)
Metformin in chronic hepatitis C virus hepatitis: Caution needed with sex-based subgroup analysis (p 719) Abstract
|
References | Full Text:
HTML,
PDF (Size: 43K)
From liver markers to life expectancy (p 720) Abstract
|
References | Full Text:
HTML,
PDF (Size: 44K)
Reply: (p 720-721) Abstract
|
References | Full Text:
HTML,
PDF (Size: 55K)
Clodronate liposomes: All sites of injection are not equal (p 721-722) Abstract
|
References | Full Text:
HTML,
PDF (Size: 53K)
Reply: (p 722) Abstract
|
References | Full Text:
HTML,
PDF (Size: 40K)
Radiofrequency ablation must be assessed by pathological methods (p 723) Abstract
|
References | Full Text:
HTML,
PDF (Size: 43K)
Reply: (p 723-724) Abstract
|
References | Full Text:
HTML,
PDF (Size: 49K)
CorrectionsCorrections (p 725) Abstract | Full Text:
HTML,
PDF (Size: 43K)
Corrections (p 725) Abstract | Full Text:
HTML,
PDF (Size: 43K)
|
|
 | ||||||||||
|
|
||||||||||||
|
|
||||||||||||
(p 376-377)
-dependent suppression of peroxisome proliferator-activated receptor 
B signaling pathway 120: (p 535-544)
hemochromatotic
cell line (p 654-659)
